Casdin Capital 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 35 US equity positions worth $1.5bn in its Q3 2024 13F filing. The largest position was BLFS at 14.5% of the reported book, followed by RVMD and WGS. Against the Q2 2024 filing, it opened 1 new position, added to 10 and reduced 6 among the top 35 holdings.
What did Casdin Capital own in Q3 2024? Top 35 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2024 |
|---|---|---|---|---|---|---|---|
| 1 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 14.5% | $218.0m | 8,707,165 | 0% | held |
| 2 | RVMD REVOLUTION MEDICINES INC | Healthcare | 12.4% | $186.6m | 4,114,283 | -7% | reduced |
| 3 | WGS GENEDX HOLDINGS CORP | Healthcare | 9.9% | $148.8m | 3,507,164 | -1% | reduced |
| 4 | LAB STANDARD BIOTOOLS INC | Healthcare | 9.2% | $137.5m | 71,254,677 | 11% | added |
| 5 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 8.9% | $134.1m | 1,073,500 | 0% | held |
| 6 | ILMN ILLUMINA INC | Healthcare | 6.5% | $97.8m | 750,000 | 56% | added |
| 7 | AVIDITY BIOSCIENCES INC | 6.4% | $95.8m | 2,084,841 | 0% | held | |
| 8 | RLAY RELAY THERAPEUTICS INC | Healthcare | 4.4% | $65.5m | 9,251,108 | 9% | added |
| 9 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.1% | $46.8m | 170,000 | 0% | held |
| 10 | EXK EXACT SCIENCES CORP | Basic Materials | 3.0% | $44.3m | 650,000 | 0% | held |
| 11 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 2.7% | $41.1m | 2,000,000 | 0% | held |
| 12 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 2.0% | $30.7m | 700,000 | 0% | held |
| 13 | 2655787D BLUEPRINT MEDICINES CORP | 2.0% | $30.2m | 326,378 | 0% | held | |
| 14 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.9% | $28.8m | 990,000 | -24% | reduced |
| 15 | CDXS CODEXIS INC | Healthcare | 1.7% | $24.9m | 8,100,000 | 305% | added |
| 16 | VCYT VERACYTE INC | Healthcare | 1.5% | $22.7m | 666,308 | -22% | reduced |
| 17 | NGNE NEUROGENE INC | 1.5% | $22.0m | 524,616 | 0% | held | |
| 18 | VERVE THERAPEUTICS INC | 1.3% | $19.3m | 3,995,571 | 31% | added | |
| 19 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.3% | $19.0m | 775,000 | 15% | added |
| 20 | TNYA TENAYA THERAPEUTICS INC | 0.9% | $13.0m | 6,732,971 | 0% | held | |
| 21 | 4D MOLECULAR THERAPEUTICS IN | 0.8% | $12.4m | 1,150,000 | 44% | added | |
| 22 | 2SEVENTY BIO INC | 0.6% | $9.4m | 2,000,000 | 0% | held | |
| 23 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.6% | $9.2m | 1,188,349 | 0% | held |
| 24 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.6% | $9.1m | 475,000 | 217% | added |
| 25 | GH GUARDANT HEALTH INC | Healthcare | 0.5% | $8.0m | 350,000 | 250% | added |
| 26 | CTNM CONTINEUM THERAPEUTICS INC | 0.4% | $5.7m | 296,666 | 0% | held | |
| 27 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.4% | $5.5m | 3,212,316 | -38% | reduced |
| 28 | GRAL GRAIL INC | 0.3% | $4.8m | 350,000 | 338% | added | |
| 29 | ABSI ABSCI CORPORATION | 0.2% | $3.7m | 973,260 | 0% | held | |
| 30 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 0.1% | $1.8m | 1,035,859 | 0% | held |
| 31 | PRME PRIME MEDICINE INC | 0.1% | $1.4m | 367,175 | 0% | held | |
| 32 | EXSCIENTIA PLC | 0.1% | $1.0m | 213,900 | 0% | held | |
| 33 | GLUE MONTE ROSA THERAPEUTICS INC | 0.0% | $455.9k | 86,014 | -67% | reduced | |
| 34 | GINKGO BIOWORKS HOLDINGS INC | 0.0% | $297.4k | 36,493 | – | new | |
| 35 | KRONOS BIO INC | 0.0% | $123.8k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.